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Abstract
Introduction: Little is known about the prognosis of moderate versus critical
carotid stenosis treated by carotid artery stenting (CAS). 
Material and methods: This was a retrospective analysis of a single-centre reg-
istry including 271 consecutive patients (69 ±9 years, 87% at high risk for sur-
gery), in whom 308 procedures were performed. The study included both symp-
tomatic (≥ 50% carotid artery stenosis) and asymptomatic (≥ 70% carotid artery
stenosis) patients. The primary endpoint was the rate of adverse events during
follow-up (range 1-48 months), defined as all-cause death or stroke. 
Results: We treated 115 critical and 193 moderate stenoses and implanted 318
stents (56% with closed cell design). Embolic protection systems were used in
296 cases (96%). The technical success rate was 98.2% in the critical stenoses
group and 99% in the moderate group (NS). During follow-up, the incidence of
the primary endpoint was 12.9% (13 pts) in the critical stenoses group and 14.7%
(25 pts) in the moderate stenoses group (estimated 3-year freedom from
death/stroke was 0.844 vs. 0.812; log-rank test p = 0.983). Left ventricular ejec-
tion fraction < 40%, significant contralateral carotid artery occlusion or steno-
sis and renal insufficiency were identified as significant predictors of the pri-
mary endpoint (p < 0.03).
Conclusions: Carotid artery stenting with embolic protection systems in patients
at high risk for carotid endarterectomy is safe. Patients with initially moderate
and critical stenoses have an identical mid-term prognosis with regard to death
and stroke.
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Introduction
It appears that in patients with only moderate asymptomatic carotid
artery stenosis (60-79%), the risk of stroke is of the order of 2% per year
or less if they are being treated medically. On the other hand, severe
stenoses (≥ 80%) are probably associated with an increased risk of stroke
of 4-5% and warrant much more aggressive revascularization [1, 2]. Carotid
artery stenting (CAS) is the method of choice for carotid artery revascu-
larization mainly in patients at high risk for surgical endarterectomy 
[3-6]. However, outcomes of CAS are significantly influenced by anatom-
ical considerations and a good post-procedural prognosis is at least par-
tially determined by the selection of optimal patients who can maximal-
ly benefit from the chosen therapeutic alternative.
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Therefore, in this retrospective analysis of
prospectively collected data in a single-centre reg-
istry, we evaluated the outcomes of CAS and com-
pared the mid-term prognosis of consecutive high-
risk patients with baseline moderate (50-89%) vs.
critical (90-99%) stenosis.
Material and methods
Between September 2005 and October 2009, 271
consecutive patients (69 ±9 years, 35% symptomatic,
87% at high risk for surgery) were enrolled, in whom
308 CAS procedures using different stents and dis-
tal embolic protective devices were performed. 
Patients
The patients were divided into 2 groups accord-
ing to the baseline degree of treated stenosis. Group
A comprised 170 patients with carotid stenosis rang-
ing from 50% to 89%, while group B had 101
patients with carotid stenosis from 90% to 99%
(Tables I-II). The study included both symptomatic
(≥ 50% carotid artery stenosis) and asymptomatic
(≥ 70% carotid artery stenosis) patients. All the
stenoses were quantified angiographically accord-
ing to the NASCET criteria [7]. Stenoses were visu-
ally assessed and quantitated independently by two
interventionalists. Quantitative analysis (Philips, Inte-
gris Allura, the Netherlands) was used only when
visual assessment of individual lesions approximat-
ed 50% stenosis for symptomatic patients or 70%
stenosis for asymptomatic patients, or when the
assessment of both examiners was disparate in
regard to categorization of lesion severity. 
The criteria for high-risk patients included 
age ≥ 80 years, history of open heart surgery, need
Parameter Stenosis < 90% Stenosis ≥ 90% Value of p
(n = 170) (n = 101)
Age [years]
Mean ± SD 69 ±8 68 ±10 0.99
Range 46-86 49-89
Men 56% 65% 0.16
Angina pectoris  20% 24% 0.54
Dyspnoea, NYHA class > 1 34% 36% 0.79
Previous myocardial infarction  37% 25% 0.04
Current smokers  42% 43% 1.00
Hypertension 89% 91% 0.67
Total plasma cholesterol [mmol/l; mg/dl] 4.2 ±0.9; 162.5 ±34.8 4.6 ±1.2; 178 ±46.4 0.01
LDL cholesterol [mmol/l; mg/dl] 2.4 ±0.8; 92.9 ±31 2.7 ±0.9; 104.5 ±34.8 0.03
HDL cholesterol [mmol/l; mg/dl] 1.1 ±0.3; 42.6 ±11.6 1.1 ±0.4; 42.6 ±15.5 0.81
Plasma triglyceride [mmol/l; mg/dl] 1.7 ±0.9; 148.8 ±78.8 1.9 ±1.3; 166.3 ±113.8 0.24
Diabetes mellitus  38% 48% 0.13
Renal insufficiency 20% 23% 0.64
Severe bronchopulmonary disease  12% 14% 0.71
Peripheral arterial disease  28% 24% 0.41
Left ventricular ejection fraction < 40% 10% 12% 0.54
History of coronary artery bypass grafting  19% 15% 0.51
Need of open heart surgery within 30 days 9% 15% 0.16
Previous coronary artery intervention  32% 31% 0.79
Known multivessel coronary artery disease 42% 34% 0.19
Previous stroke 36% 39% 0.80
Cerebral ischaemic symptoms in the last month  15% 29% < 0.01
(per procedure)
Cerebral ischaemic symptoms in the last 6 months  26% 37% 0.05
(per procedure) 
Patients with ≥ 1 risk factors  86% 85% 0.86
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for open heart surgery within 30 days, history of
myocardial infarction, known coronary multivessel
disease, left ventricular ejection fraction ≤ 40%,
severe bronchopulmonary disease, renal insuffi-
ciency, significant contralateral carotid disease and
previous carotid endarterectomy. Additionally,
patients were included if they had rejected surgi-
cal endarterectomy. All the patients provided their
written informed consent prior to the procedure.
Analysis was by intention to treat.
Definitions
Symptomatic patients had to have a history of
ipsilateral stroke, transient ischaemic attack and/or
amaurosis fugax within the last 6 months. Stroke
was defined as a neurological deficit that persist-
ed more than 24 h. Minor stroke was defined as
a new neurological deficit that resolved complete-
ly or returned to baseline within 30 days. Major
adverse events (primary end-point) were non-fatal
stroke or all-cause death.
Interventions
All the procedures were performed via the
femoral approach using a 7- or an 8 Fr guiding
catheter or a 6 Fr guiding sheath. The anticoagu-
lant and antithrombotic protocol comprised admin-
istration of 200 mg of aspirin and 300 mg of clopi-
dogrel at least 24 h prior to CAS [8]. A bolus of
heparin (5,000-10,000 IU) was administered at the
beginning of CAS to maintain an activation clotting
time of 250-300 s. The type of stent as well as the
type of embolic protection device was chosen at
the discretion of the primary operator (J.V.). Our
approach to CAS was performed as described else-
where [5, 6]. One of 3 filter devices was used: Fil-
ter Wire EZ (Boston Scientific, Mountain View, CA,
USA), Angioguard (Cordis, Johnson and Johnson,
Miami, FL, USA) or Defender (Medtronic, Min-
neapolis, MN, USA). Crotid artery stenting was per-
formed using the following self-expanding stents:
Precise RX (Cordis, Johnson and Johnson, Miami, FL,
USA), Xact (Abbott Vascular, Galway, Ireland) Carotid
Wallstent Monorail (Boston Scientific, Galway, Ire-
land), Sinus-Carotid-RX-System (Optimed, Ettlin-
gen, Germany), NexStent (EndoTex Interventional
Systems, Inc., Cupertino, CA, USA) and VascuFlex
SEC (B.Braun, Melsungen, Germany).
All the patients were repeatedly examined by
nursing staff and physicians (including neurologi-
cal examination) and all symptomatic patients were
examined by board-certified neurologists. Contrast-
induced nephropathy prevention was performed if
needed [9]. Post-procedural intracranial examina-
tion with magnetic resonance imaging (MRI) or
computed tomography (CT) was performed if the
neurological status of the patient changed. Asymp-
tomatic patients were discharged on the following
day. All the patients were asked to undergo clinical
30-day, 6-month, 1-year, and 2-year follow-ups. To
assess further clinical outcomes, all the patients
were contacted via telephone or mail. All adverse
events were confirmed by reviewing the medical
records and the national database of the departed. 
Statistical analysis
Continuous variables are expressed as mean ±
SD, discrete variables as counts and/or percentages.
Fisher’s exact test and t-test or Mann-Whitney
U test were used to explore categorical and contin-
uous baseline characteristics between groups.
Kaplan-Meier estimates were used to construct
stroke and death, and stroke-free survival curves.
These curves were compared between procedures
for moderate vs. critical stenoses using a log-rank
test. Analyses covered multiple-record data and their
variation over time. A backward stepwise multiple
Cox regression model was performed to identify 
predictors of the primary endpoint. The variables
included in the Cox regression analysis were as 
follows: age, gender, diabetes, smoking, hyperten-
sion, peri  phe  ral artery disease, severe bronchopul-
monary disease, renal insufficiency (plasma creati-
nine > 130 μmol/l), history of percutaneous coronary
intervention, history of coronary artery bypass graft-
ing, need of open heart surgery in the following 
30 days, angina pectoris > class 1 CCS, history of myo  -
cardial infarction at any time, left ventricular ejec-
tion fraction < 40%, history of stroke, cerebral ischae  -
mic symptoms in the last 6 months, cerebral ischae  mic
symptoms in the last 1 month, initial carotid artery
stenosis, residual carotid artery stenosis, contralat-
eral carotid artery occlusion, significant contralater-
al carotid artery stenosis (> 50%) or occlusion, total
cholesterol level, HDL cholesterol level, LDL choles-
terol level, triglyceride, aspirin pre-treatment, clopi-
dogrel pre-treatment, statin pre-treatment, direct
carotid stenting and fluoroscopic time. A p value less
than 0.05 was considered statistically significant.
We used the statistical software Stata, release 9.2.
(StataCorp LP, College Station, TX, USA).
Results
In a total of 271 consecutive patients (69 ±9 years,
35% symptomatic, 87% at high risk for surgery), we
treated 308 significantly stenosed carotid arteries
Stenosis < 90% Stenosis ≥ 90% Value of p
(n = 170) (n = 101) 
Statin 81% 71% 0.09
ACE inhibitor  65% 66% 1.00
β-Blocker 64% 61% 0.79
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(193 moderate and 115 critical stenoses) and
implanted 318 stents (56% with closed cell design)
(Table III). In 9 patients (3%), a bilateral carotid
artery disease was treated by CAS during a single
procedure. We performed 60 repeated procedures
(19%) because of bilateral stenosis (45 procedures,
15%) or post-CAS re-stenosis (15 procedures, 5%).
The technical success rate of CAS (residual steno-
sis ≤ 30%) was 98.7%; we did not succeed in 2 cas-
es in each group (99% vs. 98%; NS). Direct carotid
stent implantation without previous pre-dilation
was performed significantly more often in group
A patients (93% vs. 78%; p < 0.01).
In the hospital, postprocedural strokes occurred
in 5 patients (3 and 2 strokes in groups A and B,
respectively) and the 2 patients in group B expired.
Of the 2 deaths, one was due to myocardial infarc-
tion and subsequent heart failure, and one to pneu-
monia. There were no periprocedural intracranial
haemorrhages or periprocedural myocardial infarc-
tions. No further complications occurred. All the
patients were examined 30 days after the procedure. 
Between the hospital discharge and 30-day
examination, a further 2 strokes occurred (1 in each
group) and one of these patients (group B) subse-
quently expired. One patient (group B) with
a severe left ventricular dysfunction and coronary
triple vessel disease died suddenly after hospital
discharge. Overall, stroke or neurological death
occurred in 7 patients (2.6%) during the 30-day fol-
low-up. The total hierarchical occurrence of 30-day
all-cause death or stroke or myocardial infarction
was 3.7% (2.4% vs. 6%; p = 0.24).
No patients were lost from the follow-up. The
median follow-up period was 12.1 months (1-47) and
11.3 months (1-48) for groups A and B, respectively
(p = 0.03). Clinical follow-up for ≥ 12 months was
available in 52% of the patients. No other non-fatal
strokes occurred during the follow-up for ≥ 30 days.
Overall, the incidence of the primary endpoint was
14.7% (25 pts) and 12.9% (13 pts) in groups A and
B, respectively (estimated 3-year freedom from
death/stroke was 0.812 vs. 0.844; log-rank test 
p = 0.983). The outcomes are summarized in 
Figures 1 and 2. 
A backward stepwise multiple Cox regression
model identified left ventricular ejection fraction 
< 40%, significant contralateral carotid artery steno-
sis/occlusion and renal insufficiency as significant
predictors of the primary endpoint (Table IV).
Discussion
In this study, we compared the mid-term out-
comes of patients treated by CAS with special
attention to the baseline severity of carotid artery
stenosis. These results suggest that CAS with
embolic protection systems is effective and safe.
Patients with initially both moderate (50-89%) and
critical stenoses (90-99%) had an identical mid-term
prognosis with regard to death and stroke. In this
population, a backward stepwise multiple Cox
regression model identified left ventricular ejection
fraction < 40%, significant contralateral carotid
artery stenosis/occlusion and renal insufficiency as
significant predictors of the occurrence of all-cause
death or stroke.
Variable Stenosis < 90% Stenosis ≥ 90% Value of p
(n = 193 procedures)( n = 115 procedures)
Lesion located in LICA/RICA  50%/50% 43%/57% 0.29
Ostial ICA lesion  77% 74% 0.67
Tandem ICA lesion  21% 26% 0.33
Restenosis after endarterectomy 4% 7% 0.30
In-stent restenosis  5.7% 6.1% 1.00
Stenosis at baseline 75.1 ±6.8 92.6 ±3.5 < 0.01
Residual stenosis  9.3 ±10.2 10.5 ±14.3 0.92
Contralateral occlusion  11% 9% 0.70
Contralateral stenosis > 50% 37% 40% 0.63
Contrast medium [ml] 135 ±43 137 ±49 0.85
Direct stenting  93% 78% < 0.01
Mean stent length [mm] 36 ±11 39 ±13 0.02
Atropine during procedure  53% 53% 1.00
Number of post-dilations  1.1 ±0.8 1.1 ±0.8 0.71
Fluoroscopic time, median/range [min] 6.0/2.5-25.7 6.2/2.9-31.5 0.03
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We assume our findings might be interesting and
add to the medical literature. First, the present study
comprised a population of consecutive and mostly
high-risk patients with significant carotid artery dis-
ease in which one third had stenosis ≥ 90%. It
seems likely that this study presents our “real
world” clinical practice in which the vast majority
of patients can be treated by CAS with acceptable
mid-term outcomes. It is notable that according to
multivariable analysis, the symptomatic status pri-
or to intervention was not an independent predic-
tor of mid-term prognosis. Second, as was demon-
strated in the past, patients with stenosis > 80-90%
have a higher risk of future stroke [1, 2]. Moreover,
in this study, patients with critical stenoses were
more often symptomatic prior to CAS. However, this
study suggests that mid-term outcomes of patients
with baseline critical or moderate stenoses are iden-
tical after a successful CAS. Therefore, we can
hypothesize that the treatment of critical carotid
stenoses is, in comparison with moderate stenoses,
more beneficial with the maintenance of accept-
able safety. Similarly, a subgroup analysis of the
North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET) demonstrated the greatest
benefit of endarterectomy during long-term follow-
up in patients with more severe carotid disease
(stenosis 90-99%) [10]. Third, in this study, all the
strokes occurred in the first postprocedural month.
Thus, the probability of late postprocedural stroke
seems to be very low in this mainly asymptomatic
population, which was published previously [1, 2].
In the current era we should focus especially on the
appropriate patient selection and fine-tuning of CAS
technique [11, 12]. Interestingly, the preferable
catheterization technique in this study was direct
stent implantation and this approach was suc-
cessful in more than 80% of the cases with critical
carotid artery stenosis. Fourth, the results of the
multiple regression analysis suggest that the occur-
rence of all-cause death or stroke was determined
both by generally known risk factors (left ventricu-
lar dysfunction and renal insufficiency) and by the
extent of carotid artery disease (significant con-
tralateral stenosis or occlusion). 
Several interventional groups have attempted to
show the benefit of protective embolic devices in
reduction of periprocedural embolism [13]. Although
no randomized data are available, we feel that
closed cell designed stents, direct stent implanta-
tion without previous dilation and use of appropri-
ate protective embolic devices are the most impor-
tant factors improving the early postprocedural
outcome of treated patients [5, 6]. Furthermore, the
proper selection of patients including a thorough
assessment of the overall clinical risk also plays an
important role in the indication of CAS. Therefore,
we should bear in mind the possible predictors of
the mid-term adverse events as were suggested in
this study.
This single-centre study must be understood in
the context of its limitations. All the procedures
were performed by a single cath-lab team with
long-term experience with CAS. This fact seems to
be important mainly in the light of the recent dis-
cussion of the three randomized studies compar-
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Figure 1. Kaplan-Meier curves for freedom from death
or stroke
Figure 2. Kaplan-Meier curves for freedom from
death
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log-rank test p = 0.983 log-rank test p = 0.981
Stenosis       < 90%          ≥ 90% Stenosis       < 90%          ≥ 90%
Variable Hazard ratio 95% confidence interval Value of p
Left ventricular ejection fraction < 40% 3.34 1.41-7.88 0.006
Contralateral carotid artery stenosis or occlusion 3.36 1.28-8.78 0.014
Renal insufficiency 2.56 1.14-5.77 0.023
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ing CAS and carotid endarterectomy that are criti-
cized by many interventionalists because of the
insufficient endovascular experience of operators
participating in the trials [14-17]. In contrast to those
studies, a recently published CREST study [18] with
similar results of CAS and carotid endarterectomy
had a lead-in phase to train less experienced oper-
ators prior to the trial. Hence, the present results
again underline the essential role of appropriate
physician training and credentialing [19-22]. 
In conclusion, CAS with embolic protection sys-
tems in patients at high risk for carotid endarterec-
tomy is safe. Patients with initially both moderate
(50-89%) and critical stenoses (90-99%) treated by
CAS had an identical mid-term prognosis with
regard to death and stroke. 
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